In these analyses of tumor tissue from patients enrolled in the open-label, Phase 2 ABRAZO study, 97% of evaluable tumors exhibited ≥1 BRCA1/2mut and there was 95% concordance between known gBRCA1/2mut and tBRCA1/2mut; this is perhaps unsurprising given the importance of gBRCAmut in breast cancer pathology, and the fact that patients were selected based on gBRCAmut status. The gene discussed is BRCA1; the disease is breast carcinoma.